Virpax Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRPX Virpax Pharmaceuticals Inc
FDCFF Forum Energy Metals Corp
AFMD Affimed NV
ARVN Arvinas Inc
FOUR Shift4 Payments Inc
UK Ucommune International Ltd
CRDF Cardiff Oncology Inc
TRNR Interactive Strength Inc
OMGA Omega Therapeutics Inc
ACST Acasti Pharma Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.


Last Trade
0.0276 (3.58%)
B/A Size

Market Hours

Closing Price
Day's Change
0.01 (1.32%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.